Electronic cigarettes, also called e-cigarettes, are advertised as a safer, more convenient, and socially acceptable alternative to smoking tobacco cigarettes. Widely available in retail stores and on the…
Med Lett Drugs Ther. 2013 Nov 11; 55(1429):89-90
Electronic cigarettes, also called e-cigarettes, are advertised as a safer, more convenient, and socially acceptable alternative to smoking tobacco cigarettes. Widely available in retail stores and on the Internet, their use has been increasing over recent years, primarily among smokers, but also among non-smokers.
Electronic cigarettes, also called e-cigarettes, are battery-operated nicotine-delivery devices that resemble tobacco cigarettes. They deliver vapor containing a mixture of nicotine and either propylene glycol…
Med Lett Drugs Ther. 2012 Nov 26; 54(1404):93-4
Electronic cigarettes, also called e-cigarettes, are battery-operated nicotine-delivery devices that resemble tobacco cigarettes. They deliver vapor containing a mixture of nicotine and either propylene glycol or glycerol. E-cigarettes are widely available in retail stores and on the internet in labeled strengths ranging from zero to high levels of nicotine and in flavors such as tobacco, mint, coffee, cherry, bubblegum, and chocolate. They are advertised as a healthier alternative to smoking a tobacco cigarette and, although not FDA-approved, as a smoking cessation tool.
The most effective drugs available for treatment of tobacco dependence are bupropion ( Zyban , and others and varenicline (Chantix) . The FDA recently ordered the manufacturers of both to add boxed warnings…
Med Lett Drugs Ther. 2009 Aug 24; 51(1319):65
The most effective drugs available for treatment of tobacco dependence are bupropion ( Zyban , and others and varenicline (Chantix) . The FDA recently ordered the manufacturers of both to add boxed warnings about the risk of psychiatric symptoms and suicide to their prescribing information (FDA Alert, 7/1/2009).
The nicotine receptor partial agonist varenicline ( Chantix - Pfizer) appears to be the most effective drug available to treat tobacco dependence, but the FDA has added a warning to the package insert about…
Med Lett Drugs Ther. 2008 Jul 14; 50(1290):53
The nicotine receptor partial agonist varenicline ( Chantix - Pfizer) appears to be the most effective drug available to treat tobacco dependence, but the FDA has added a warning to the package insert about neuropsychiatric symptoms and exacerbations of preexisting psychiatric illness associated with its use. Agitation, hostility, depressed mood, suicidal ideation and suicidal behavior have been reported as postmarketing adverse events in patients who took varenicline and stopped smoking and in those who took the drug and continued to smoke.
When the nicotine receptor partial agonist varenicline ( Chantix – Pfizer) was first marketed, The Medical Letter concluded that it was moderately effective in increasing smoking cessation rates. 1 More…
Med Lett Drugs Ther. 2007 Nov 19; 49(1274):93-6
When the nicotine receptor partial agonist varenicline ( Chantix – Pfizer) was first marketed, The Medical Letter concluded that it was moderately effective in increasing smoking cessation rates. 1 More recent publications and the clinical experience of Medical Letter consultants now suggest that varenicline is the most effective drug available for this indication, more effective than nicotine replacement therapy or bupropion SR (Zyban) . 2,3 A word of caution: exacerbations of psychiatric illness have been reported in patients who took higher-than-recommended starting doses of varenicline. 4,5 1. Varenicline (Chantix) for tobacco dependence. Med Lett Drugs Ther 2006; 48:66. 2. P Wu et al. Effectiveness of smoking cessation therapies: a systemic review and meta-analysis. BMC Public Health 2006; 6:300. 3. K Cahill et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007; (1):CD006103. 4. R Freedman. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007; 164:1269. 5. I Kohen and N Kremen. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007; 164:1269. Download U.S. English
The FDA has reported that 5106 elderly patients with dementia treated with atypical (second generation) antipsychotics in 17 randomized controlled trials had a higher mortality rate (4.5% vs. 2.6%) than those…
Med Lett Drugs Ther. 2005 Aug 1; 47(1214):61-2
The FDA has reported that 5106 elderly patients with dementia treated with atypical (second generation) antipsychotics in 17 randomized controlled trials had a higher mortality rate (4.5% vs. 2.6%) than those receiving placebo. Most of the deaths were due to cardiovascular and infectious causes (such as pneumonia). The drugs used in the trials were aripiprazole (Abilify) , olanzapine (Zyprexa) , quetiapine (Seroquel) , and risperidone (Risperdal) . As the increase in mortality was considered a class effect, the FDA advisory also included ziprasidone (Geodon) , clozapine (Clozaril) and the olanzapine/fluoxetine combination (Symbyax) . The manufacturers of all of these drugs will be required to add a "black box" warning to their labeling.
Many patients ask physicians to help them stop smoking. Since nicotine gum and patches were first marketed (Medical Letter, 26:47, 1984; 34:37, 1992), more data have become available on their effective use,…
Med Lett Drugs Ther. 1995 Jan 20; 37(940):6-8
Many patients ask physicians to help them stop smoking. Since nicotine gum and patches were first marketed (Medical Letter, 26:47, 1984; 34:37, 1992), more data have become available on their effective use, and new formulations of the drug have been developed. Because of its slower rate of absorption, nicotine from gum or patches does not produce the pleasure some people associate with cigarette smoking, but it can relieve the irritability, difficulty in concentrating and other symptoms that occur after withdrawal from smoking.
Three nicotine-releasing adhesive patches for the skin ( Habitrol - Ciba-Geigy; Nicoderm - Marion Merrell Dow; and PROSTEP - Lederle) have been approved by the US Food and Drug Administration to aid withdrawal…
Med Lett Drugs Ther. 1992 Apr 17; 34(868):37-8
Three nicotine-releasing adhesive patches for the skin ( Habitrol - Ciba-Geigy; Nicoderm - Marion Merrell Dow; and PROSTEP - Lederle) have been approved by the US Food and Drug Administration to aid withdrawal from smoking. Nicotrol (Parke-Davis) may also be approved soon. All the manufacturers recommend using the patches in conjunction with a behavioral modification program.
Human alpha1-proteinase inhibitor ( Prolastin Cutter), possibly better known as alpha1-antitypsin (ATT), is now available in the USA for replacement therapy in patients with emphysema who have a congential…
Med Lett Drugs Ther. 1988 Mar 11; 30(761):29-30
Human alpha1-proteinase inhibitor ( Prolastin Cutter), possibly better known as alpha1-antitypsin (ATT), is now available in the USA for replacement therapy in patients with emphysema who have a congential deficiency of the protein.